Candel Therapeutics, Inc.
CADL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8 | $7 | $4 | $5 |
| G&A Expenses | $0 | $4 | $4 | $0 |
| SG&A Expenses | $5 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $13 | $11 | $8 | $8 |
| Operating Income | -$13 | -$11 | -$8 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $6 | $16 | -$6 |
| Pre-Tax Income | -$11 | -$5 | $7 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$5 | $7 | -$14 |
| % Margin | – | – | – | – |
| EPS | -0.205 | -0.093 | 0.23 | -0.4 |
| % Growth | -120.5% | -140.5% | 157.5% | – |
| EPS Diluted | -0.205 | -0.093 | 0.23 | -0.4 |
| Weighted Avg Shares Out | 55 | 51 | 32 | 36 |
| Weighted Avg Shares Out Dil | 55 | 51 | 32 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$4 | $8 | -$13 |
| % Margin | – | – | – | – |